Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

Trial Profile

The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatrogon (Primary)
  • Indications Growth disorders; Short stature; Somatotropin deficiency; Turner's syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GeNeSIS
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society
    • 19 Apr 2017 New trial record
    • 04 Apr 2017 Results (n=5076) analysing near adult height gains in Somatropin treated children with growth disorders from the GeNeSIS observational study, presented at The 99th Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top